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Abstract 
Achieving high oral bioavailability for drugs is a key design objective in drug development. It is not surprising 
then that with the growing expectation of peptides as future drugs, there has also been an increasing interest in 
developing oral peptide therapeutics. Brought to the fore are questions such as what makes peptides orally 
bioavailable and how this can be achieved; questions which have inspired research into the area for decades. 
Early research in the area focused on linear peptides with more recent literature focusing on cyclic peptides, 
motivated in part by cyclic peptides like cyclosporine A that have demonstrated drug-like oral bioavailability. In 
this review, we take a look at research on the oral bioavailability of peptides, focusing on factors that affect 
passive permeability.   
 
1. Introduction 
As evident from recent literature on cyclic peptides
1-4
 and the papers published in this issue,
5-13
 there is 
significant interest in cyclic peptides as therapeutics. The reason for this interest is founded not only on the 
belief that cyclic peptides have advantages over other drug modalities but also the growing perception that they 
are a privileged sub-class among peptides as a whole because of their greater potential to be 'drug-like', as 
opposed to linear peptides for example. Supporting this trending view is the growing number of examples of 
cyclic peptides or analogues thereof that have oral activity or oral bioavailability.
14-20
 Achieving high oral 
bioavailability is one of the most important goals in drug design, as it will result in lower doses of the 
administered drug, fewer side effects and, potentially, higher patient compliance.  
The purpose of this review is to reflect on past and recent studies to provide perspectives on what affects 
peptide oral bioavailability. Although we will highlight some studies on linear peptides, we will focus on cyclic 
peptides and factors that affect their passive absorption, and briefly mention factors that affect other 
mechanisms of absorption towards the end of the review. 
 
2. From the 'gut' to the 'blood' 
Oral bioavailability is defined as the fraction of an orally administered drug that reaches systemic circulation. 
Once consumed, the drug must cross the enterocyte layer (in addition to other biological barriers) to reach blood 
vessels on the other side, as illustrated in Figure 1. Passage from one side of the cell layer to the other is referred 
to as cell permeability, and involves two possible pathways: the paracellular pathway, in which the drug passes 
through tight junctions between enterocytes; and the transcellular pathway, in which the drug passes through 
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enterocytes. Transcellular transport involves either active transport, which is mediated by transporters 
embedded in the cell membrane, or passive transport, in which the drug diffuses across the lipid membrane. It is 
important to distinguish between these various transport mechanisms because different factors are likely to have 
differing effects on peptide permeability depending on the transport pathway.  
 
3. On the road of oral bioavailability 
Seminal studies by Lipinski,
21
 Veber
22
 and others
23
 on the properties of drugs that are favorable for oral 
bioavailability have shaped much of the modern view of 'drug-likeness', but have lead to the prescription that 
peptides are poor drugs. As these studies have been based mainly on small molecules (e.g. in Lipinski's study,
21
 
87 peptides were excluded), the question often asked is whether these guidelines apply to peptides? In other 
words, are new guidelines required to determine drug-likeness of peptides? 
Inspiring the quest for a more focused understanding of what governs peptide oral bioavailability is the example 
of cyclosporin A (CsA), a peptide drug regarded to have revolutionized human organ transplant surgery. 
Although there is some controversy about its discovery,
24-26
 early studies noted that CsA was orally 
bioavailable;
25
 however, the result was initially difficult to reproduce because its formulation affected the 
measured oral bioavailability.
25-26
 Since the initial report of its oral bioavailability in humans of 30% (with 
values ranging from 10 to 60%) when administered within a chocolate drink,
27
 subsequent studies have 
confirmed the importance of the delivery concoction, with reports of higher oral bioavailability (e.g. 40% for a 
microemulsion formulation of CsA called Neoral
28
) and reduced variability in absorption depending on the 
formulation used. Although the formulation clearly has an effect on oral bioavailability, an in-depth discussion 
of peptide-drug formulation is beyond the scope of this review; instead, we will focus on the structural features 
of peptides that affect their absorption. In this respect, CsA is distinguished from other peptides with low oral 
absorption by its cyclic backbone, the presence of non-canonical amino acids (e.g. N-methylated amino acids) 
and its conformational flexibility – specific details on these factors will be discussed in Section 4. 
Figure 2 arranges selected studies on peptide oral bioavailability in a chronological display, starting with the 
discovery of CsA in the early 1970's and highlighting examples of cyclic peptides with moderate to high oral 
bioavailability. Although we made every effort to include all relevant studies, we are aware that the timeline, 
limited by size, is not exhaustive in its coverage. The timeline can perhaps be divided into two periods, starting 
with the 'dawn' of peptide oral bioavailability studies around the 1990's, which mainly encompasses works from 
the research groups of Burton
29-33
 and Borchardt.
34-38
 Although not a research article, the work by Humphrey
39
 
is highlighted in this period because its review of 20 peptides (some linear and others cyclic) and related drugs 
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identified factors that affect peptide absorption that are still intensely studied today. Following this period, is the 
'renaissance' led mainly by the research groups of Lokey and Jacobson,
16, 40-46
 and Kessler.
15, 47-50
 As shown in 
Figure 2, these groups reported cyclic peptides with very promising oral bioavailability (e.g. a somatostatin 
analog with ~10% oral bioavailability
15
 and a leucine-rich peptide with ~30% oral bioavailability
16
), which 
were surprising because they challenged the widely-held perception that peptides have poor oral bioavailability. 
Along with these studies, contributions from the groups of Fairlie
18, 51-52
 and Craik
17, 53
 and others
54
 have 
progressed our understanding of what makes peptides cross membranes. 
  
4. Factors affecting passive permeability 
Of the different transport pathways, a greater flux of drugs across the epithelial layer can in principle be 
achieved through passive transport if it is accessible to the drug. In this section, we discuss some of the key 
factors that affect passive permeability of peptides, including hydrogen bonds, lipophilicity, size, flexibility and 
structure.  
4.1. Hydrogen bonds 
As peptides transition across a lipid bilayer, they encounter differing solvent environments, e.g. they move from 
an aqueous environment with a high dielectric constant to the bilayer core which has a low dielectric constant 
(Figure 3). In the aqueous environment, the hydrogen bond acceptors and donors of the peptide participate in 
hydrogen bonds with solvent water molecules, unless they are shielded from the solvent because of the local 
conformation or are involved in internal hydrogen bonds. These solvent interactions are disrupted upon entering 
the bilayer, leading to an energetic penalty that disfavors permeability.
29
 Based on this premise, any peptide 
modification that reduces solvent interactions (e.g. through modification of hydrogen bond donors and 
acceptors
15-17
 or by shielding them from solvent
18, 45, 51
) should enhance peptide permeability (Figure 3A). 
Based on studies of linear peptides by Conradi et al.,
29
 it was proposed that a major impediment to peptide 
passive absorption is the energy required to break water-peptide hydrogen bonds in order for the peptide to 
enter the cell membrane. A subsequent study
31
 on N-methylated peptides found that modification of backbone 
amides (i.e. potential hydrogen bond donors) increased permeability, supporting the aforementioned hypothesis 
and distinguishing the hydrogen bond network as a determinant of peptide permeability.
29, 33-34
 Echoing these 
earlier studies, more recent studies on cyclic peptides have confirmed that the hydrogen bond network also 
affects passive permeability of cyclic peptides,
40-41, 45
 and N-methyation of exposed amides enhances 
permeability.
15-17
 For example, White et al.
16
 report, using an elegant chemical approach, the discovery of a 
cyclic N-methylated peptide with small-molecule-like oral bioavailability. Design of peptides with high oral 
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bioavailability is also possible using structure-guided approaches, such as using NMR experiments to 
specifically target amides for modification;
17
 these studies highlight the utility of structural information,
15-16, 18, 
40, 45, 48, 51
 as the structure defines which amides are exposed and contribute to the energetic penalty limiting 
permeability. Although hydrogen bonds (both internal and external) certainly play a role in determining 
permeability, it has been difficult to predict permeability based on hydrogen bond counts (either internal or 
external) because other factors also influence permeability,
53
 such as structure, flexibility and lipophilicity.  
4.2. Lipophilicity 
Cyclic peptides require a degree of lipophilicity to cross a membrane – they can be neither too lipophobic nor 
too lipophilic. Peptides that are too lipophobic do not readily insert into the membrane, and therefore cannot 
cross to the other side, whereas peptides that are too lipophilic may insert too readily into the membrane, overly 
favouring the membrane-bound state and resulting in poor overall transport. The factors that contribute to 
peptide lipophilicity are varied and include hydrophobicity, which helps drive the peptide into the hydrophobic 
lipid bilayer core via the hydrophobic effect (a phenomenon related more to the cohesiveness between water 
molecules than the ‘attraction’ between hydrophobic surfaces). Another factor that affects lipophilicity is the 
hydrogen bond network; so, although lipophilicity is represented here as a separate factor to hydrogen bonds, 
the two are not completely independent of each other. 
It is widely-established that lipophilicity is an important parameter for drug permeability of small molecules and 
peptides.
35, 39, 55
 For cyclic peptides, there is a strong positive correlation between lipophilicity and cell 
permeability, 
42-43, 45, 53
 confirming that lipophilicity is also a key determinant of permeability for cyclic peptides 
as well; however, the trend reverses for very lipophilic compounds.
53
 Within the positive correlation region, 
side-chain substitutions that increase (or decrease) lipophilicity are correlated with an increase (or decrease) in 
permeability.
42-43, 45, 53
 N-methylation, which was mentioned above as a means of modifying the hydrogen bond 
network, also introduces additional methyl groups that increase lipophilicity, resulting in increased 
permeability. (In cases where lipophobic peptides that are highly N-methylated have been reported to have high 
membrane permeability, it is thought that those peptides are predominantly transported by mechanisms other 
than passive diffusion.) At high lipophilicity, however, reduced aqueous solubility and increased affinity for the 
membrane results in a negative correlation between lipophilicity and permeability,
53
 suggesting that caution 
should be exercised at high lipophilicity. Studies on small molecules have identified that other caveats are 
associated with increasing lipophilicity, including higher levels of target promiscuity
56
 and increased risks of 
toxicity.
57
  
4.3. Ionization  
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As for small molecules, it is expected that the charge state of a peptide will affect its diffusion through a lipid 
membrane. Specifically, an uncharged peptide would diffuse more readily through a lipid environment than a 
charged peptide. Indeed, increasing the content of charged amino acids in cyclic peptides is linked to reduced 
permeability;
42, 46, 53
 reduced lipophilicity is also observed, indicating that charged peptides have lower lipid 
solubility and therefore limited diffusion through a lipid bilayer. 
4.4. Solubility 
Poor aqueous solubility, which can arise from high lipophilicity, limits the fraction of the administered amount 
that is available in solution in its desired form to move across the membrane; according to Fick’s Law of 
diffusion, the lower effective concentration (or more precisely the lower concentration gradient across the 
diffusion path) will result in reduced passive transport. The fraction that is not soluble will aggregate, 
potentially acquiring characteristics that are unfavorable for passive diffusion, such as increased size. Poor 
aqueous solubility also leads to variability in experimental results. For example, in early studies, very low oral 
absorption was sporadically observed for CsA,
25-26
 which is very poorly soluble in water, although it is now 
known that CsA exhibits high oral absorption provided an appropriate formulation is used.
28
 In in vitro 
permeability experiments, poor solubility can result in low recovery, producing permeability results that are 
lower than predicted
42
 or expected based on structure-permeability correlations.
53
  
4.5. Size 
Adapting the Stokes-Einstein relation to cyclic peptides, the diffusion coefficient (which represents the rate of 
diffusion) is expected to be inversely proportional to the molecular radius (i.e. the hydrodynamic radius if the 
peptide is solvated), a parameter which is in turn dependent on molecular weight. Using NMR diffusion 
measurements, it was observed that as molecular weight increases, so does size (in general) and shape 
(modulated by tertiary structure), resulting in larger radii and slower diffusion for cyclic peptides.
58
 Attempts 
have been made to consider the molecular radius in computational predictions of cyclic peptide permeability
42
 
and larger cyclic peptides tend to have poor permeability.
46
 Additionally, cyclic peptides that aggregate or self-
associate will have slower diffusion because of their larger effective radii.
58
 For example, the tendency of a 
cyclic penta-leucine peptide to aggregate was used to explain its relatively lower permeability.
51
 Aside from the 
diffusion coefficient, other factors are also correlated to molecular size; for example, larger peptides tend to 
have more hydrogen bond donors and acceptors, increasing the associated effect on permeability as discussed 
above. So far, the largest cyclic peptide with drug-like oral bioavailability is CsA (which 11 amino acids in 
length); it would be interesting to discover cyclic peptides that lie far beyond this (apparent) size frontier. 
Towards this goal, it has been proposed that utilizing the structural features of CsA that distinguishes it from 
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other peptides with low oral absorption (e.g. a cyclic backbone, non-canonical amino acids, and conformational 
flexibility) may be the key.
16
  
4.6. Flexibility 
In the discussion of the factors that affect permeability so far, it has been convenient to describe (implicitly) 
peptides as static systems with fixed and defined properties that determine whether they will be membrane 
permeable. However, even though cyclic peptides are expected to be more rigid than their linear counterparts, 
they can display varying degrees of dynamics depending on their chemical composition,
59
 which would affect 
how they are described in terms of permeability 'factors' and how they are expected to permeate. For example, 
rather than attempting to characterize cyclic peptides according to discrete hydrogen bond counts, it might be 
more appropriate to recognize that each hydrogen bond donor (or acceptor) has varying degrees of exposure to 
solvent and therefore varying degrees of contribution to the thermodynamics underlying permeability.  
Furthermore, the permeability process involves the movement of these dynamic systems between different 
solvent environments; consequently, the change in environment can induce change in peptide conformation 
(with the level of change dependent on how constrained the peptide is). Solvent-dependent conformational 
polymorphism of some membrane permeable peptides, such as CsA, led to the conformational hypothesis, 
which speculates that peptides that can shape-shift can negotiate into alternative energy pathways that are more 
favorable for permeability (Figure 3B).
16, 32, 40-42
 In chloroform, a solvent which mimics the environment of the 
lipid bilayer core, CsA enters a conformational space that is different to that in an aqueous environment but one 
that is more compatible with its current environment by hiding most of its hydrogen bond donors and acceptors 
in internal hydrogen bonds.
60
 The ability to change conformations may represent a strategy by which cyclic 
peptides can compensate for having other properties that are unfavorable for permeability, such as a larger size. 
The conformational hypothesis has been explored in more detail for cyclic hexapeptides, resulting in the finding 
that the change in conformation and its associated change in energy of insertion is highly predictive of passive 
permeability.
41
 The benefit of conformational change has been interpreted to mean that flexibility is important, 
but the important distinction is that although flexibility is required for conformational change, it is more 
important that the peptide can ‘flex’ into compatible conformations without being too flexible and not sampling 
the ‘desired conformations’ with sufficient frequency. Other studies on cyclic hexa- and hepta-peptides have 
suggested that rigidity is another permeability-determining factor.
18
 Although relatively rigid peptides may 
diffuse through membranes, it remains to be seen whether cyclic peptides of the size of CsA or larger that are 
rigid will be more permeable than those that can shift into energetically-preferred conformations. 
4.7. Structural motifs 
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It has been proposed that β-turn motifs and cis-peptide bonds are beneficial for peptide permeability.
35, 38
 
48, 50
 
The increased permeability of linear lipophilic peptides containing β-turn structural features has been explained 
by their increased lipophilicity (and improved hydrogen bond properties).
35
 This hypothesis might explain why 
some structural features have been observed more frequently in membrane-permeable peptides, including CsA: 
they are associated with physicochemical properties that are more favorable for permeability. For example, 
compared to an extended linear peptide, a β-turn-containing peptide would have one less hydrogen bond donor 
and acceptor completely solvent-exposed because they are involved in an internal hydrogen bond. Other 
structural motifs aside from the β-turn might also be beneficial for peptide permeability provided that they are 
associated with physicochemical properties that are more favorable for permeability. As well as assisting in 
passive diffusion of cyclic peptides,
38
 β-turn motifs have also been observed in cyclic lipophobic peptides that 
are not passively transported,
48
 suggesting that β-turn motifs might be useful structural components for 
accessing other transport pathways.  
4.8. Cyclization 
Here we attempt to link cyclization to the other factors that affect passive permeability. Compared to linear 
peptides of the same size, cyclic peptides sample a more restricted conformational space; if the conformations 
that favor permeability lie within this space and can be adequately sampled, then cyclic peptides will adopt 
those conformations more frequently than their linear counterparts, and therefore more frequently permeate the 
membrane. These conformations may be ones that contain β-turn motifs, exposed lipophilic atoms and side-
chains, have sufficient flexibility, and/or a large proportion of internal hydrogen bonds. Indeed, early studies 
comparing the permeability of cyclic and linear peptides observed significantly increased permeation for cyclic 
peptides, which was explained by increased lipophilicity and β-turn motifs.
38
 In backbone-cyclic peptides, the 
absence of free N- and C-termini reduce potential interactions between the peptide and solvent, which is 
desirable for permeability. A cyclic structure can also be more compact compared to a linear one, reducing its 
collision profile in solution and allowing it to diffuse faster through the membrane. Finally, cyclic peptides are 
typically more stable against chemical or enzymatic degradation than linear peptides, and therefore more 
peptide is available at each step of the transport process, resulting in greater overall amount transported. 
 
5. Other factors affecting absorption 
So far, we have focused on passive absorption; however, as alluded to in Figure 1, there are many barriers that 
affect oral bioavailability of peptides.
61-62
 In Figure 4, we highlight these barriers, starting with the peptide in 
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solution and ending with metabolism after absorption, and also identify some specific factors relevant to each 
barrier.  
Within the gastrointestinal tract, the administered peptide is susceptible to degradation by enzymes or acidic 
conditions in the stomach, reducing the amount available to be absorbed. Compared to linear peptides, cyclic 
peptides can show enhanced metabolic stability,
63-64
 and therefore potentially can have longer residence times 
within the gastrointestinal tract. It is worth noting that peptides containing cyclic structures formed by disulfide 
bonds may be affected by thiol-disulfide exchange reactions
65
 that would perturb their structures and 
subsequently might reduce their metabolic stabilities. 
Bulk flow within the gastrointestinal tract is not uniform and is limited above the epithelial layer, resulting in an 
unstirred water layer that is protected from convective mixing forces, slowing absorption of peptides from the 
bulk flow. Also on top of the enterocyte layer is the mucosal layer, which is a viscoelastic barrier that contains a 
large proportion of negatively-charged glycoproteins that will hinder movement of peptides due to ionic 
interactions. Furthermore, it has been shown that peptides >6.5 kDa have poor permeation across the mucus 
layer.
66
 However a cut-off in molecular size of peptides is difficult to define, as the mucus is a very dynamic 
system. 
Once past the mucus layer, peptides can passively diffuse across the cell layer and/or be transported actively 
and/or diffuse through the paracellular pathway. Paracellular transport is thought to be favored by small 
lipophobic peptides.
36
 Using mirror image peptides, it was demonstrated that cyclic peptides can be actively 
transported across cells.
49
 Active transporters, or more specifically efflux pumps, can also pump peptides back 
into the gastrointestinal lumen. For example, the amount of CsA transported across cells is affected by its 
binding to the efflux pump P-glycoprotein I.
67
  
Even after a peptide crosses the cell layer, other metabolic processes can affect the amount in systemic 
circulation. For example, the first-pass effect can reduce the amount of active parent peptide that reaches 
systemic circulation after absorption because of metabolic processes in the liver. Enzymes in serum can further 
reduce the amount of peptide once it is in circulation. There are many obstacles preventing a peptide drug from 
reaching its target site of action after oral administration and to make an evolutionary analogy, it is certainly a 
case of “survival of the fittest”. 
 
6. Conclusions and Future Perspectives 
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It is alluring to imagine a future where peptides form a significant proportion of approved drugs. For this 
aspiration to become a reality traditional drug-design paradigms dictate that we can easily deliver peptide drugs 
as oral therapeutics. Here, we have discussed some factors that affect peptide absorption, a precondition to oral 
bioavailability, including hydrogen bonds, lipophilicity, size, flexibility and structure. It is important to 
recognize that there is an interplay between many of these factors and that different factors will have differing 
effects depending on the transport pathway. Understanding these factors will hopefully enable the design of 
peptides that are orally bioavailable.  
Given the intense interest in peptides amongst pharmaceutical and biotechnology companies at present we 
believe that the future for peptide-based drugs is bright, despite the challenges associated with oral delivery.  
Cyclic peptides offer particular advantages over linear peptides and represent a particularly promising class of 
molecules in our opinion. We hope that the information and discussion in this article will stimulate researchers 
to address some of the challenges in this field. 
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Figure Captions 
 
Figure 1. Cell permeability and transport pathways. For an orally administered peptide to be absorbed into 
the blood system, it must pass through several barriers as depicted here, including a layer of epithelial cells. 
Transport across this cell layer is called cell permeability, and includes paracellular (between cells and through 
tight junctions) and transcellular (through cells). Transcellular transport is divided into either active (carrier 
mediated) or passive transport across the membrane lipid bilayer, as illustrated in the inset. 
 
Figure 2. A timeline of studies on peptide oral bioavailability, highlighting selected studies. Published 
studies and some of their main findings are shown and are grouped roughly according to their associated 
research groups. They are colored according to the decade in which they were published (the colors for each 
decade are shown on the arrow in the middle of the figure) for studies on cyclic peptides; articles describing 
mainly linear peptides are shaded with a grey background. Selected cyclic peptides reported to have interesting 
permeability or oral bioavailability are shown in circles with their chemical structures, reported oral 
bioavailability and size. 
 
Figure 3. Passive permeability of cyclic peptides across a lipid bilayer. Panel A shows the surface and stick 
representation of a cyclic hexa-peptide (with a red background) that has poor permeability across the lipid 
bilayer (schematically represented as a head group with hydrophobic tails). The surface of the peptide 
comprises hydrophobic regions (orange), which would favor the membrane core environment, and polar regions 
(red and blue), which interact with solvent water molecules if they are exposed to the solvent. After N-
methylation of specific amides that are solvent-exposed, the peptide (within the green box) has increased 
permeability. As a result of N-methylation, the surface has an increased hydrophobic surface area and reduced 
polar surface area, as well as reduced interactions with solvent water molecules. Panel B shows cyclosporine A 
undergoing conformational change as it transitions into the membrane. The change in conformation facilitates 
permeability. 
 
Figure 4. Barriers to absorption and associated factors. After being dissolved in solution, a peptide is 
challenged by the contents of the gut, and then must pass through the mucus and unstirred water layer, followed 
by the cell membrane. Before reaching systemic circulation, a peptide will encounter the first-pass effect (i.e. it 
might be metabolized in the liver). Adapted from a figure by Humprey.
39
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Figure 1. Cell permeability and transport pathways. For an orally administered peptide to be absorbed into 
the blood system, it must pass through several barriers as depicted here, including a layer of epithelial cells. 
Transport across this cell layer is called cell permeability, and includes paracellular (between cells and 
through tight junctions) and transcellular (through cells). Transcellular transport is divided into either active 
(carrier mediated) or passive transport across the membrane lipid bilayer, as illustrated in the inset.  
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Figure 2. A timeline of studies on peptide oral bioavailability, highlighting selected studies. Published studies 
and some of their main findings are shown and are grouped roughly according to their associated research 
groups. They are colored according to the decade in which they were published (the colors for each decade 
are shown on the arrow in the middle of the figure) for studies on cyclic peptides; articles describing mainly 
linear peptides are shaded with a grey background. Selected cyclic peptides reported to have interesting 
permeability or oral bioavailability are shown in circles with their chemical structures, reported oral 
bioavailability and size.  
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Figure 3. Passive permeability of cyclic peptides across a lipid bilayer. Panel A shows the surface and stick 
representation of a cyclic hexa-peptide (with a red background) that has poor permeability across the lipid 
bilayer (schematically represented as a head group with hydrophobic tails). The surface of the peptide 
comprises hydrophobic regions (orange), which would favor the membrane core environment, and polar 
regions (red and blue), which interact with solvent water molecules if they are exposed to the solvent. After 
N-methylation of specific amides that are solvent-exposed, the peptide (within the green box) has increased 
permeability. As a result of N-methylation, the surface has an increased hydrophobic surface area and 
reduced polar surface area, as well as reduced interactions with solvent water molecules. Panel B shows 
cyclosporine A undergoing conformational change as it transitions into the membrane. The change in 
conformation facilitates permeability.  
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Figure 4. Barriers to absorption and associated factors. After being dissolved in solution, a peptide is 
challenged by the contents of the gut, and then must pass through the mucus and unstirred water layer, 
followed by the cell membrane. Before reaching systemic circulation, a peptide will encounter the first-pass 
effect (i.e. it might be metabolized in the liver). Adapted from a figure by Humprey.  
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